Now accepting Telehealth appointments. Schedule a virtual visit.

Practical impact of COVID-19 on CHR patients, individualizing DOR treatment & more

Practical impact of COVID-19 on CHR patients, individualizing DOR treatment & more

Dr. Gleicher's live webinar on DHEA was attended by over 4,000 viewers.

May 2020 CHR VOICE Digest

During April, the coronavirus and COVID-19, in all spheres of life, continued to dominate the nation’s existence. That, of course, also applies here at CHR. We are, however, very pleased to report that so-far only one of our staff members has contracted the virus. She has been home for over a month and is recovering well. CHR has continued to function “normally,” if anything can still be considered to function “normally” these days. In practical terms, CHR, in contrast to most other IVF centers in New York City and the country, never shut down. We have curtailed non-urgent clinical activities but continued to offer all treatments our patients and CHR concurred were urgent, relying on the telemedicine capabilities we've developed over the years for our international and US long-distance patients.

The COVID-19 pandemic, unsurprisingly, also still dominates this issue of the VOICE. But we, in addition, also are discussing some clinical issues that attracted enormous attention during a worldwide virtual professional infertility conference in April. The conference was expected to attract notmore than 1,000 virtual attendees; yet, it ended up with over 14,000 fertility specialists joining online. A lecture on the clinical utilization of dehydroepiandrosterone (DHEA) by CHR’s Medical Director and Chief Scientist, Norbert Gleicher, MD, attracted the largest number of immediate downloads at the conference (over 4,000, and a few thousand additional ones over the following days). Because of this unexpected and overwhelming interest in the subject of low functional ovarian reserve (LFOR),we decided to initiate with this issue of the VOICE a detailed series of articles on how to individualize treatments in women with LFOR. Here we present the first installment.

In this issue of the CHR VOICE, we cover:

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    

 


We have helped women bring over
17,800 babies into the world.

DISCOVER YOUR TREATMENT OPTIONS

 

You Might Also Enjoy...

The Voice June 2022

We are pleased to present here the June issue of the CHR VOICE, after which we traditionally start a two-month summer hiatus for this newsletter, returning to our regular monthly publication schedule with the start of the new 2022-2023...

The Voice May 2022

April was a hectic month at the CHR because the deadline period for abstract submission to the Annual Meeting of the ASRM is always hectic.

The Voice April 2022

March was an unusually busy month at the CHR and not only clinically. CHR’s investigators saw several important papers published, with one in NATURE Medicine, in detail presented in the March issue of the VOICE, receiving unusual media attention

The Voice March 2022

With Spring per schedule knocking on the door, the mood in the world feels anything but spring-like. The deadly and cruel Russian war machine is already for weeks invading the independent country of Ukraine.

The Voice February 2022

In the shortest and traditionally coldest month of the year, we welcome you to the February issue of our monthly newsletter. Hopefully, history will show that we reached a point in the Covid-19 pandemic with more hope than at any time slot before.